key: cord-0945647-beobqnox
authors: Barzkar, Farzaneh; Ranjbar, Mitra; Sioofy-Khojine, Amir-Babak; Khajehazad, Mohammadamin; Vesal Azad, Roya; Moradi, Yousef; Baradaran, Hamid Reza
title: Efficacy and safety of chloroquine and hydroxychloroquine for COVID-19: A comprehensive evidence synthesis of clinical, animal, and in vitro studies
date: 2020-12-17
journal: Med J Islam Repub Iran
DOI: 10.47176/mjiri.34.171
sha: 4e0527fac9d7266e7c307ee61d935da15c509d0a
doc_id: 945647
cord_uid: beobqnox

Background: The world is facing a pandemic of COVID-19, a respiratory disease caused by a novel coronavirus which is now called SARS-CoV-2. Current treatment recommendations for the infection are mainly repurposed drugs based on experience with other clinically similar conditions and are not backed by direct evidence. Chloroquine (CQ) and its derivative Hydroxychloroquine (HCQ) are among the candidates. We aimed to synthesize current evidence systematically for in vitro, animal, and human studies on the efficacy and safety of chloroquine in patients with COVID-19. Methods: The Cochrane Library, Google Scholar, PubMed (via Medline), Embase, Scopus, and Web of Science, MedRxiv, clinical trial registries including clinicaltrials.gov, ChiCTR (Chinese Clinical Trial Registry), IRCT (Iranian Registry of Clinical Trials), and the EU Clinical Trials Register. We used the Cochrane tool for risk of bias assessment in randomized studies, the ROBINS tool for non-randomized studies, and the GRADE methodology to summarize the evidence and certainty in effect estimates. Results: The initial database searching retrieved 24,752 studies. Of these, 15,435 abstracts were screened and 115 were selected for full-text review. Finally, 20 human studies, 3 animal studies, and 4 in vitro studies were included in this systematic review. The risk of bias within studies was unclear to high and the overall certainty in evidence-based on GRADES- was very low. HCQ may be effective in clinical improvement in a subset of patients with COVID-19. However, the frequency of adverse events was higher in patients taking HCQ compared to standard of care alone. In contrast, animal studies, did not report any adverse effects. Furthermore, clear benefit of the drug in the survival of the animals has been reported. Most in vitro studies indicated a high selectivity index for the drug and one study that used a human coronavirus reported blockage of virus replication. Conclusion: Current evidence background is limited to six poorly conducted clinical studies with inconsistent findings which fail to show significant efficacy for HCQ. Safety data is also limited but the drug may increase adverse outcomes. Routine use of the drug is not recommended based on limited efficacy and concerns about the drug safety especially in high-risk populations.

From the black plague in the 14 th century Europe to the cholera pandemics of the 19 th century and the 1918 Spanish flu, epidemics have always been a subject of concern and a cause of mass mortality as well as considerable economic, social, and psycho logic harm to populations throughout history. The most recent one, to date, has been the COVID-19 pandemic, caused by SARS-CoV-2, a member of the family Coronaviridae, that is mainly characterized by severe acute respiratory syndrome. This virus appeared in China in December 2019 and rapidly spread worldwide, creating a public health emergency around the world in 6 months.

Since SARS-CoV2 is a novel pathogen, no standardized treatment is currently available. One proposed agent is chloroquine (CQ), classically known as an antimalarial and immunomodulatory agent. Preclinical evidence suggests that clinical research on CQ in COVID-19 patients is justified (1) . In a previous SARS-CoV epidemic, it was proposed that CQ could be considered as a treatment (2, 3) . During the first months of the COVID epidemic, a letterto-the-editor claimed that CQ has shown efficacy and safety in an ongoing multicenter study in China for pneumonia caused by SARS-CoV-2, and it was recommended to be included in treatment regimens for COVID-19 pneumonia (4) . Therefore, CQ and Hydroxychloroquine (HCQ) have been considered as potential treatments for COVID- 19 .

Whether systematic reviews of preclinical studies can accurately predict clinical outcomes is controversial. However, preclinical research can provide useful information about the biological plausibility of human drug trials (5) . Its special settings that enable direct study of the mechanisms of disease as well as drug pharmacodynamics and pharmacokinetics can aid clinical decision-making (6) .

In this systematic review, we aimed to comprehensively synthesize in vitro, animal, and clinical evidence background for the effectiveness and safety of CQ, including its sulfate and phosphate salts, and Hydroxychloroquine for treating patients with COVID-19. 

Human controlled studies (including interventional and observational studies), animal studies, and in vitro studies evaluating the effect of CQ, Hydroxychloroquine, or other quinine derivatives on coronavirus infections, including SARS, MERS, and COVID-19, up to June 30, 2020 were included. No limitation was used based on language, publication status, or length of follow-up.

The Cochrane Library, Google Scholar, PubMed (via Medline), Embase, Scopus, and Web of Science, MedRxiv; and clinical trial registries, including clinicaltrials.gov, ChiCTR (Chinese Clinical Trial Registry), IRCT (Iranian Registry of Clinical Trials), and the EU Clinical Trials Register.

The search strategy was developed based on study questions and relevant key words by a medical librarian (R.V.A.) and a physician (F.B.) with systematic review experience for all information sources. An update search was done on July, 30, 2020 for further human studies.

All retrieved records were comprehensively screened based on title by 2 authors independently (F.B. and M.A.K.). Relevant studies were imported into a citation manager (Endnote X7) for screening the abstract after removal of duplicated sources. The abstracts matching the eligibility criteria were selected and categorized into groups based on study type and participants by one reviewer (M.A.K. or F.B.) and the full-texts of the studies were retrieved. We contacted the authors when we could not access the full-texts. The full-texts of the in vitro studies as well as the animal models were reviewed by a virologist (B.S.). The full-texts of clinical studies were evaluated for eligibility by 2 physicians (F.B. and MAK). The references of included articles were hand-searched for further relevant studies.

To ensure uniform and comprehensive data extraction among different data extractors, the reviewers developed Microsoft Access forms and tables, including information recommended in the Cochrane Handbook of Systematic Reviews of Interventions (7) . These items included the name of the first author, publication year, region, descriptions of study design, participants, interventions, comparisons, outcomes and results, as the sources of funding and key conclusions by the original study authors. Data were extracted by the same review authors who screened the article full-texts. excluded based on full-text, as they were reviews or perspective articles.

The update search retrieved 1628 studies that were screened by title by 1 author. A total of 248 abstracts were screened and 82 full-text articles were screened by 2 authors independently. Finally, we included 18 non-randomized studies and 6 randomized human studies.

The PRISMA flow diagram is presented in Figure 1 .

Human Studies: We included 6 RCTs and 14 nonrandomized controlled human studies, all of which were conducted among hospitalized patients. None of the studies were placebo-controlled. Also, pregnant and breastfeeding women as well as patients with underlying conditions were excluded. Most studies compared the recommended dose of HCQ daily (ranging from 400mgs/day to 800mgs/day) with drug regimens without HCQ/CQ. Also, 3 studies used a high dose of HCQ, 6 had AZI, and 2 had Lopinavir/ritonavir as part of their control regimen. The follow-up duration varied among the studies and ranged from 7 to 30 days (Tables 1 and 2) . Allocation concealment and blinding procedures were neither explained in the article nor in the protocol. The outcomes reported were completely different from the ones initially planned in the protocol. In the protocol, the researchers planned to evaluate viral clearance and immunologic response. However, they merely reported clinical outcomes in the article.

Unclear description of randomization is given. Antiviral regimens were not the same between groups.

Open-label randomized trial. With control group receiving standard care. Reporting of outcomes was complete and dropout frequency was 6 out of 75. Use of intervention varied among participants especially regarding the timing in relation to symptom onset.

Randomized controlled trial. The pharmacist distributing the drugs was not blinded, which might have been the source of uncertainty in blinding of participants and personnel.

Open-label randomized study with 6-item randomization blocks. Both the patients and the personnel were aware of the randomization group. Selective reporting was unlikely because the protocol was available, and all the predetermined outcomes have been reported. Appropriate use of intention-to-treat analysis makes it unlikely for incomplete reporting to affect study results. 6.

Open-label randomized study with 4-item randomization blocks (according to the protocol but not mentioned in the published report). There was a baseline difference between the groups in "days from onset to treatment." Concealment of randomization was done using sealed envelopes. The study protocol was available and the risk of selective reporting was low. However, the published results are preliminary and there is serious risk of data incompleteness.

http://mjiri.iums.ac.ir Med J Islam Repub Iran. 2020 (17 Dec); 34.171. Observational study with well-matched between-group baseline characteristics, and the same dosage of chloroquine for all patients. Inconsistency in measurement and recording of the outcomes is suspected.

Children who usually have milder course of disease were not included to the treatment group, while they were included in the comparison group. No placebo was used in comparison group. Participants and personnel were not blinded. There was a high dropout rate (6/26) in the treatment group with reasons potentially relevant to the side effects of hydroxychloroquine, including admission to ICU and treatment cessation. An intention-to-treat analysis should have been used.

Retrospective cohort analysis of hospital data. Patient selection based on international criteria. Confounding variables addressed by propensity scores in analysis. No information was given on how the exposure use was confirmed. No information was given on how outcomes were assessed. The study protocol was not available to assess the selective reporting. No information was given on missing data.

Retrospective study of hospital data on PCR confirmed COVID19 patients. Augmented inverse probability of treatment weighted (AIPTW) estimates of the average treatment effect (ATE) were used to account for confounding. Data were extracted using artificial intelligence from data systems and manually from medical text reports. Exposures measured according to hospital-registered prescriptions only.

Retrospective multicenter cohort. Random sample of patients admitted to 25 hospitals. The exposure dosage and regimens differed across the study sample. A low proportion of patients used HCQ alone. There was inadequate description of how outcome measurement and data extraction were done and there is a high risk of bias due to the variability in exposures and outcome measurements across hospitals. 6.

Multinational registry analysis (retrospective observational) on patients with PCR-confirmed COVID-19. Confounding was adjusted for in statistical analysis. No protocol was available; therefore, risk of bias due to selective reporting cannot be estimated. Outcome assessment is suspected to differ significantly across the study centers and due to the observational nature of the study. 7.

Retrospective observational study on patient data from 1 hospital. The study methodology was poorly reported. All patients had PCR-confirmed COVID-19. There was significant difference in the frequency of comorbidities between HCQ and control groups, and consequently, a serious risk of bias due to confounding. No information was given on missing data. No study protocol was available to confidently assess selective reporting. 8.

Retrospective observational study in 1 veterans' hospital. All patients had PCR-confirmed COVID19. Propensity score analysis was used to address confounding. Exposure was defined based on the information from hospital registry of drug dispensing for each patient. No study protocol was available to assess selective reporting. Outcome assessment may cause moderate risk of bias due to the observational nature of the study. 9.

Retrospective cohort study. All patients had PCR and culture-confirmed COVID-19. Cardiovascular disease was more common among the control group. The treatment was initiated at an earlier stage of the infection in this study. It is not clear how exposure to the treatments was assessed. No study protocol was available to assess the risk of selective reporting. 10. Retrospective observational study at a quaternary, acute care hospital. Patients had PCR confirmed COVID-19. Confounding was adjusted using propensity score matching/analysis. The exposure was evaluated by patient exposure to the drug before or during the admission and thus may vary across participants. No study protocol was available and risk of selective reporting could not be assessed. 11. Retrospective observational study on critically-ill (selection bias) inpatients with CT and PCR-confirmed COVID19. There was no significant baseline difference in confounding variables between groups. Patient classification (based on dug exposure) may have been subject to error because mere prescription may not show drug use by the patient. No information is given on how the outcome measurements were standardized. 12. A multicenter retrospective observational study on inpatients with PCR-confirmed COVID-19. Treatment regimens were uniform across hospitals. There was moderate risk of bias due to confounding because of the nonrandomized nature of the study and that HCQ was used among patients with more severe disease. This may underestimate the effects of chloroquine. This confounding was partially adjusted for statistically. 13 . Retrospective multicenter cohort based on HER data. The study design made it susceptible to bias due to confounding and misclassification. Drug administration was well documented. There was moderate risk of bias due to missing outcome data. 14. Initial results of a prospective observational study with an available protocol. Patients had PCR-confirmed COVID-19. Confounding variables have been well adjusted for. Although the study was observational, enough documentation was performed for the degree of exposure to drugs. Outcome measurement was at moderate risk of bias due to the nature of nonblinded and observational nature of the study.

Animal Studies: One of the animal studies used SARS-CoV-1 in BALB/c female mice and tested the efficiency of Amodiaquine and CQ, with a dose response design detecting the virus replication in lung homogenates. The other 2 animal studies used HCoV-OC43 virus as the model. One of these 2 studies aimed at identifying the effect of CQ-sulphate in adult C57BL/6 mice followed by studying the protective effect of the drug transferred to litters by placenta or milk of the drug treated mothers. The other study optimized the detection of a luciferase labelled virus in adult BALB/c mice but used the drug CQ as a control to block the virus replication and control the background luciferase detection in treated mice. The study characteristics of the 3 animal studies are summarized in Table 3 in Appendix. Interestingly, 2 of the animal studies included in vitro examinations as part of their design, which were added to the in vitro studies.

Among the 6 randomized human studies included to the systematic review, the risk of bias due to random sequence generation was unclear among 2 studies. Allocation concealment introduced a high risk of bias in 1 study and was unclear in 2 other studies. Only 1 study was blinded. Two studies were at high risk of bias due to incomplete outcome data, and 1 study was at high risk of bias due to selective reporting. The details are presented in Table 4 .

Among the 14 nonrandomized human studies, 7 were at moderate overall risk of bias, 5 were at serious risk, and 2 had a critical risk of bias. The details are presented in Table  5 .

Risk of bias was also assessed in animal studies, and they were found to be generally reliable ( Table 6) .

Human Studies: Because of the heterogeneity in the type of included studies, different methods of outcomes assessment, and the statistical methods for summarizing the results, we could not combine the results in a meta-analysis. Therefore, we synthesized the results qualitatively.

Clinical Response: One study showed a reduced mean of days of having fever for patients in the HCQ group compared to the control (2.2 vs 32) and another study showed fewer number of days with fever for the HCQ group compared to the control group. Taking HCQ was also associated with shortened duration of cough in 1 study (an average of 2 vs 3.1 days). In 1 study, administering HCQ was related to a higher rate of clinical improvement within a course of 28 days, whereas in 2 other studies, HCQ treatment was associated with a higher rate of progression to severe illness.

Adverse Events: The most notable adverse events were GI events, death due to unclear cause, and cardiac adverse events, all of which were more prevalent among the HCQ groups compared to controls (SOC). One study that considered the incidence of "any" adverse event showed a higher incidence among the HCQ group compared to that of the control group. The incidence of other symptoms, such as headache, rashes, nausea, and weakness, were low in both groups, without a significant difference between the HCQ and the control groups. 7 Tables 4 to 6 present the synthesis of the effect estimates per outcome and Table 7 is the summary of findings in GRADE format.

Animal Studies: Two animal studies showed the effectiveness of CQ in mice models using a wild type HCoV-OC43 and another recombinant rOC43-ns2DelRluc from 10/10 9/12 -- 8 which the ns-2 gene was replaced with a reporter gene. In both models, intracerebral inoculation of the virus was treated with CQ and improved the survival of the infected mice compared with the animals in the control group. The models were not similar: one study examined survival in suckling mice but the other assessed survival of adult mice. Also, the viruses were not identical in the 2 models. CQ in another mice model did not block infection by SARS-CoV. Hydroxychloroquine may have little positive to no effect on radiological progression but the evidence is very uncertain and more research is needed. ICU Admission 5433 (5 observational studies)

The evidence is very uncertain whether chloroquine/hydroxychloroquine could affect the rate of ICU admission.

Cardiac Adverse Events 501 (5 RCTs) VERY LOW b,j,k Hydroxychloroquine may significantly increase the rate of adverse events especially QT prolongation and cardiovascular death but the evidence is very uncertain. Explanations a. Three studies reported this outcome. None was blinded and one was not randomized. b. There is significant heterogeneity in trial results. This might be due to differences in outcome measurements and also study populations. c. Total number of patients in the control group=110. confidence intervals d. There is special concern for publication bias due to the recent emergence of the disease and the timing of this review. Trials that are not published yet may show different results. e. None of the studies were placebo-controlled and the standard-of-care which was the control intervention in all of the studies, differed within and across studies. The methods of outcome measurement also differed across studies. Another concern is about time from symptom-onset to treatment initiation which is different and not described in adequate detail. f. Total number of patients in the control group for this outcome =111 g. Precision is downgraded due to the wide confidence intervals of effect estimates as presented in the results table. h. Please refer to risk of bias table.

i. Total number of events in the control group was 21.

j. The quality is downgraded due to risk of bias concerns. None of the studies measured the adverse effects systematically. There is a special concern for under detection of side effects in the included studies. k. Total number of events in control group was 12. l. total number of events in the control group was 9.

http://mjiri.iums.ac.ir Med J Islam Repub Iran. 2020 (17 Dec); 34.171.

In vitro Studies: Recent studies of COVID-19 showed promising results with CQ and HCQ in Vero cell models reported in 3 studies published in 2020 (13) . Also, all studies, except 1 which used human primary cells, reported the efficiency of the drug in cell models. Although the selectivity index of the studies varied, they generally show that the drug is safe. Additionally, the amount of virus used to assess the blocking effect of the drugs on virus replication varied between studies, and higher viral inoculates correlated with a higher dose of drug needed to block the virus infection. All in vitro studies supported the antiviral effect of CQ and HCQ in human coronaviruses, including SARS, MERS, and COVID-19. Factors that may limit the applicability of these results include the use of established cell lines, mostly Vero cells, and only 1 or 2 strains of each virus. Figure 2 presents a concept map of the interaction between HCQ and different mechanisms involved in pathogenesis of COVID19.

HCQ has been proposed to have antiviral activity and has been used against many viral infections, including HIV (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) , influenza (27) (28) (29) (30) (31) (32) , chikungunya virus (33) (34) (35) (36) (37) (38) (39) , and many other viruses (36, 37, (40) (41) (42) (43) (44) , albeit with variable levels of clinical effectiveness. Our systematic review reveals a consistently positive antiviral effect for HCQ in vitro and animal studies; however, these effects varied significantly in human studies. Most of human studies used the drug at later stages of the illness compared with animal studies, which may be the reason for the inconsistency in findings across human and animal studies. Moreover, previous studies have shown that animal studies cannot accurately predict clinical outcomes in humans (6) . This concept has been reproduced in our systematic review. Thus, based on these limited findings, we cannot conclude whether HCQ is a safe and effective antiviral agent for the treatment of COVID19.

COVID-19 is asymptomatic to mildly symptomatic in most patients. However, in a smaller number of patients with more severe disease, severe inflammatory response, cytokine storm, and microphage activation syndrome, it may lead to ARDS and multiorgan failure, which may potentially lead to death (45, 46) . Cytokine release syndrome (CRS) is associated with higher adverse outcomes among patients with COVID19 (47) (48) (49) and may indirectly decrease viral clearance via decreasing T-cell number and function (50, 51) . Immune modulating drugs such as steroids have been shown to improve outcomes (52, 53) . Hydroxychloroquine is one of these potential agents that modulates immune reaction by decreasing pro-inflammatory cytokine release and decreasing the risk of macrophage activation syndrome in patients with systemic lupus erythematous without significant immunosuppression (54) (55) (56) (57) (58) (59) (60) . In our systematic review, 2 included clinical studies evaluated immunologic markers in COVID-19 patients under treatment with HCQ and found significant reduction in inflammatory cytokines in these patients, although the overall quality of these studies was very low (61, 62) . Three other studies compared cytokines (IL-6 and TNF-alpha) between HCQ and SOC patients and did not find any significant difference, but our certainty in these results is also very low (63) (64) (65) (66) (67) . 

In light of the evidence suggesting hypercoagulable state and its possible role in the pathogenesis of severe COVID-19, this particular pathway may be an important target for treatment (68, 69) . Anticoagulants have been shown to decrease mortality in COVID-19 patients (70) . In 1 study, patients with COVID19-associated pneumonia had a markedly higher level of D-dimer and higher platelet count than patients with non-COVID-19-associated pneumonia (71) . A multicenter study that included 150 patients with COVID-associated ARDS found that >95% of the patients had an elevated D-dimer level and 50 of 57 of the tested patients were positive for lupus anticoagulant antibodies (72) . Nevertheless, these results are inconsistent with another study which found no association between antiphospholipid antibodies and COVID-19 prothrombotic state (73) . In another cohort of hospitalized patients with COVID-19, the hypercoagulable state in these patients is more consistent with a severe inflammatory state than DIC (74) . HCQ has been shown to decrease thrombotic events in patients with antiphospholipid syndrome by interfering with assembly of endosomal NADPH oxidase-2, which is involved in thrombotic events and affects inflammatory state in antiphospholipid syndrome (58, 75) .

Cardiovascular events, including acute cardiac injury, shock, and arrhythmias, were present in 7.2%, 8.7%, and 16.7% of patients with COVID-19, according to a cohort study of hospitalized patients (76) . These patients are at an increased risk of in-hospital events, including ICU admission and death (77) (78) (79) . In a recent study, a combination of azithromycin and HCQ was associated with an increase in the QTc interval to more than 500 milli seconds in 11% of the 84 patients with COVID-19. This effect was significantly more common among patients with renal failure (80) . In a retrospective cohort study on multinational databases collectively including millions of patients, it was found that new users of HCQ alone were not at a significantly increased risk of adverse effects; nonetheless, its combination with azithromycin was associated with an increased risk of death associated with cardiovascular events among patients with rheumatoid arthritis (81) . These findings present indirect evidence on cardiovascular outcomes among chloroquine users. Moreover, the doses and diseasedrug interaction and effect on the heart may differ considerably in COVID-19. Therefore, clinicians should be especially cautious about the cardiac adverse effects of chloroquine, especially its combination with azithromycin or Oseltamiovir, and their possible synergistic activity with COVID-19 effects on the heart (82).

Toxicity with quinine agents, including chloroquine and HCQ, has also been reported to cause pulmonary side effects, including an ARDS-like syndrome (83) (84) (85) , bronchiolitis obliterans organizing pneumonia (BOOP) (86) , and pulmonary edema (87) (88) (89) . A retrospective study of Wuhan patients with COVID-19 reported nervous system involvement among 78 of 214 (36.4%) patients as a part of the clinical presentation in COVID-19. It involves both the periph-eral and the central nervous system, with symptoms ranging from dizziness and headache to impairments in taste and smell and even to stroke, seizures, and encephalitis. The proposed pathophysiologic mechanism is a direct brain invasion as in SARS and MERS (90) . Seizure has also been reported with chloroquine use, although this was not confirmed in trials as an adverse effect, clinicians should be cautious when prescribing this drug in patients with epilepsy (91) .

The available studies have significant methodological limitations, many of which are due to the difficulties associated with the special circumstances during a pandemic. Whether chloroquine can be clinically effective remains a question. One potential reason for the inconsistency between preclinical and clinical studies can be the interval between infection and treatment initiation, which may affect the potential antiviral effects of chloroquine. We recommend researchers to design trials of chloroquine at earlier phases of the infection and among outpatients. We also recommend systematic and globally homogenous monitoring and reporting of the side effects and clinical outcomes.

Based on current evidence, we recommend clinicians against the routine use of chloroquine/HCQ in patients with COVID-19, as the drug has not shown clinical efficacy and may be associated with life-threatening side effects, especially when prescribed with other routinely prescribed medications, such as azithromycin and Oseltamiovir. Thus, special care must be taken for patients at risk for QT prolongation.

The quality of the included studies was low to very low. No placebo-controlled studies were available and only one of the studies was blinded. There was significant variation in outcomes and methodology across the studies, thus, a meta-analysis could not be conducted. All of the studies included hospitalized patients only and the results cannot be generalized to all patients with COVID-19.

We present a holistic viewpoint by synthesizing the in vitro, animal, and human (observational and interventional) evidence on the benefits and risks associated with the use of chloroquine/HCQ in patients with COVID-19 with a rigorous methodology. A few systematic reviews have already been published that focused on the same review question. However, our study is unique in presenting a holistic approach combining the results from preclinical studies with nonrandomized and randomized human studies and presenting a basic science based clinically oriented viewpoint.

There is insufficient evidence to draw conclusions on the efficacy and safety of chloroquine and Hydroxychloroquine based on current evidence. Available studies have significant methodological limitations and the results are http://mjiri.iums.ac.ir Med J Islam Repub Iran. 2020 (17 Dec); 34:171.

A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19

Effects of chloroquine on viral infections: An old drug against today's diseases?

Development of antiviral therapy for severe acute respiratory syndrome

Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies

Modernizing the Bradford Hill criteria for assessing causal relationships in observational data

Can prospective systematic reviews of animal studies improve clinical translation?

Cochrane handbook for systematic reviews of interventions

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

SYRCLE's risk of bias tool for animal studies

Evaluation of the risk of bias in non-randomized studies of interventions (ROBINS-I) and the 'target experiment'concept in studies of exposures: rationale and preliminary instrument development

RoB-SPEO: A tool for assessing risk of bias in studies estimating the prevalence of exposure to occupational risk factors from the WHO/ILO Joint Estimates of the Work-related Burden of Disease and Injury

Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline

Non-invasive bioluminescence imaging of HCoV-OC43 infection and therapy in the central nervous system of live mice

Complete clearance of cutaneous warts with hydroxychloroquine: Antiviral action?

Therapeutic potential of chloroquine added to zidovudine plus didanosine for HIV-1 infected children

Effect of Tenofovir/Emtricitabine/Efavirenz with and without Chloroquine in Patients with HIV/AIDS C3: Double Blinded Randomized Clinical Trial

The Effect of Chloroquine on Immune Activation and Interferon Signatures Associated with HIV-1

TSCQ study: a randomized, controlled, open-label trial of daily trimethoprim-sulfamethoxazole or weekly chloroquine among adults on antiretroviral therapy in Malawi: study protocol for a randomized controlled trial

Reduction of immune activation with chloroquine therapy during chronic HIV infection

hydroxyurea and didanosine as initial therapy for HIV-infected patients with low viral load: safety, efficacy and resistance profile after 144 weeks

Hydroxychloroquine, hydroxycarbamide, and didanosine as economic treatment for HIV-1

Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial

Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders

Assessment of chloroquine as a modulator of immune activation to improve CD4 recovery in immune nonresponding HIV-infected patients receiving antiretroviral therapy

Comparison of hydroxychloroquine with zidovudine in asymptomatic patients infected with human immunodeficiency virus type 1

Hydroxychloroquine treatment of patients with human immunodeficiency virus type 1

Different pH requirements are associated with divergent inhibitory effects of chloroquine on human and avian influenza A viruses

Enhancement of T cell-mediated immune responses to whole inactivated influenza virus by chloroquine treatmentin vivo

Chloroquine is effective against influenza A virus in vitro but not in vivo. Influenza Other Respir Viruses

Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model

In vitro inhibition of human influenza A virus replication by chloroquine

Mechanism of uncoating of influenza B virus in MDCK cells: action of chloroquine

Chloroquine phosphate treatment of chronic Chikungunya arthritis. An open pilot study

Effectiveness of chloroquine and inflammatory cytokine response in patients with early persistent musculoskeletal pain and arthritis following chikungunya virus infection

On chikungunya acute infection and chloroquine treatment. Vector Borne Zoonotic Dis

Chloroquine inhibited Ebola virus replication in vitro but failed to protect against infection and disease in the in vivo guinea pig model

Lack of protection against ebola virus from chloroquine in mice and hamsters

Efficacy of combination DMARD therapy vs. hydroxychloroquine monotherapy in chronic persistent chikungunya arthritis: a 24-week randomized controlled open label study

A randomized controlled trial of chloroquine for the treatment of dengue in Vietnamese adults

FDA-approved Drug, Prevents Zika Virus Infection and its Associated Congenital Microcephaly in Mice

Chloroquine and Its Derivatives Exacerbate B19V-Associated Anemia by Promoting Viral Replication: e669

Chloroquine inhibits Rhodococcus equi replication in murine and foal alveolar macrophages by iron-starvation

Chloroquine administration does not prevent Nipah virus infection and disease in ferrets

An evaluation of Chloroquine as a broad-acting antiviral against Hand, Foot and Mouth Disease

The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The experience of clinical immunologists from China

Cytokine storm in COVID-19: pathogenesis and overview of antiinflammatory agents used in treatment

The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The experience of clinical immunologists from

Underlying Vulnerabilities to the Cytokine Storm and Adverse COVID-19 Outcomes in the Aging Immune System

Cytokine storm syndrome in coronavirus disease 2019: A narrative review

Cytokine Storm in COVID-19-Immunopathological Mechanisms, Clinical Considerations, and Therapeutic Approaches: The REPROGRAM Consortium Position Paper

Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19)

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China

Corticosteroids in COVID-19 ARDS: Evidence and Hope During the Pandemic

Rethinking the role of hydroxychloroquine in the treatment of COVID-19

Chloroquine inhibits production of TNF-alpha, IL-1beta and IL-6 from lipopolysaccharidestimulated human monocytes/macrophages by different modes

Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis

Arthritis and use of hydroxychloroquine associated with a decreased risk of macrophage activation syndrome among adult patients hospitalized with systemic lupus erythematosus

Mechanism of Action of Hydroxychloroquine in the Antiphospholipid Syndrome

Chloroquine treatment influences proinflammatory cytokine levels in systemic lupus erythematosus patients

Hydroxychloroquine decreases Th17-related cytokines in systemic lupus erythematosus and rheumatoid arthritis patients

Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19

Hydroxychloroquine application is associated with a decreased mortality in critically ill patients with COVID-19

Efficacy and safety of chloroquine or hydroxychloroquine in moderate type of COVID-19: a prospective open-label randomized controlled study

Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries

Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial

Hydroxychloroquine in patients with COVID-19: an open-label, randomized

Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan

Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2

High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study

the pathogenesis of thromboembolic disease in COVID-19 patients: Could be a catastrophic antiphospholipid syndrome? medRxiv

Hypercoagulability of COVID-19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis

Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, and Neurological Diseases: A Mini-Review

Cardiac and arrhythmic complications in patients with COVID-19

Association of Cardiovascular Manifestations with In-hospital Outcomes in Patients with COVID-19: A Hospital Staff Data

End-stage Heart Failure with COVID-19: Strong Evidence of Myocardial Injury by 2019-nCoV

Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China

The QT Interval in Patients with SARS-CoV-2 Infection Treated with Hydroxychloroquine/Azithromycin

Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study

Chloroquine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe respiratory syndrome in the context of coronavirus

Preliminary safety results of a randomized, double-blinded, phase IIb clinical trial

Adult respiratory distress syndrome in babesiosis

Chloroquine poisoning with respiratory distress and fatal outcome

Fatal adult respiratory distress syndrome after quinine overdose

Quinine-induced bronchiolitis obliterans and organizing pneumonia

Acute pulmonary edema caused by quinine

Mefloquine-induced eosinophilic pneumonia

Chloroquine-induced drughypersensitivity

Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease

A systematic review to assess seizure risk with chloroquine therapy in persons with epilepsy

Chloroquine showed no effect on virus titers in vivo when used intraperitoneally. However, it had a statistically non-significant effect in reducing the virus titers in lung tissues. Amodiaquine had no effect at the highest concentration used in the study (150mg/kg) where it did not reduce the virus titers at lung tissues. NotesThe efficiency of the drugs was also tested in vitro in African green monkey cells using different strains of the SARS-Cov including Urbani, Toronto 2, Frankfurt 1, CHUK-W1 strains and showed no effect for Chloroquine and two other salts of it but were blocked by Amodiaquine in vitro. Also, both drugs were claimed to be well tolerated but the data was not shown. In the study two parts were included. 200μl of different dilutions of Chloroquine (corresponding to 1, 5 or 15 mg/kg of body weight) daily starting from 1 days before/after labor was administered subcutaneously. Subsequently, 5-day suckling mice were infected intracerebrally with virus containing 1x103 copy numbers of the virus genome and were followed for the outcome as death. The follow up study involved administering chloroquine at the high dose of 15 mg/kg prepartum and switch the litters for breast feeding. The same way the pups were infected, and the survival was followed for 60 days post-infection. A negative control group included no drug intervention. Survival of the pups challenged with live virus 1000 TCID50 intracerebrally 5 days postpartum.

A log rank test indicated that the survival curve for litters that were treated prepartum with 15mg/kg chloroquine was significantly different from the survival curves for the pups that were treated prepartum with 5mg/kg (P= 0.0237), 1mg/kg (P= 0.0001). 100% survived treated 15 mg/kg prepartum (97.4% treated postpartum). The survival was dose dependent. The results of the follow-up study showed that switching the litters between groups of mothers to detect the effect of the transplacental or milk delivered chloroquine. The drug was effective when transferred by milk and not transplacentally. NotesThe efficiency of the drug was also tested in vitro using HRT-18 cells and concentration higher than 0.16 μM results in a decline in the number of HCoV-OC43 copies determined by qRT-PCR. Additionally, the 15mg/kg drug group survived 100% when used prepartum meaning no adverse effect was associated with the usage of the drug in this study. Mice were inoculated with chloroquine and the virus then was administered intracerebrally at 100 TCID50 using rOC43-ns2DelRluc, and bioluminescence intensity was measured daily to quantify the virus replication. The tissues including brain and spinal cord were studied for the Photon flux and the presence of viral proteins by western blotting.

The control mice did not get chloroquine before being infected with the virus. Dosage-forms Chloroquine was administered to mice 2 h before viral inoculation (day 0; 30 mg/kg) and then administered daily according to a previous study of HCoV-OC43-WT (Keyaerts et al., 2009). ComparisonDrug to PBS as placebo Number of subjects 3 mice in virus group and 3 mice in virus + drug group Tissue Whole brain and spinal cord Length of follow-up 4 days post infection OutcomesSurvival and the bioluminescence expressed by virus replication as well as the western blot analysis of the luciferase activity of the expressed protein in brain and spinal cord.

No signals were detected in mice treated with Chloroquine, and all of them survived, whereas all mice receiving PBS displayed increased bioluminescence and died, demonstrating a significant difference relative to the individual controls.Also, western blot analysis supported the data of the mice being successfully infected when virus was inoculated. NotesThe main aim of the study was to optimize and validate the detection of the virus infection in mice and drug treatment was used as a control for the whole experiment. The initial dose of 30 mg/kg chloroquine has been reported to be toxic in C57BL/6 mice as reported above but was used in BALB/c mice in here followed by half dose thereafter.